Pernix Therapeutics (NASDAQ:PTX) released its earnings results on Thursday. The specialty pharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, Morningstar.com reports. The firm had revenue of $37.16 million during the quarter.
Shares of PTX stock traded down $0.13 during trading on Friday, hitting $0.69. The company’s stock had a trading volume of 294,354 shares, compared to its average volume of 130,048. Pernix Therapeutics has a 52 week low of $0.59 and a 52 week high of $3.30.
Separately, ValuEngine raised Pernix Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, August 20th.
TRADEMARK VIOLATION WARNING: This story was posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thestockobserver.com/2018/11/10/pernix-therapeutics-ptx-releases-quarterly-earnings-results.html.
Pernix Therapeutics Company Profile
Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry.
Recommended Story: Hedge Funds – How They Work For Investors
Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.